Investigating a peptide's role in reversing Alzheimer's neurodegeneration
Official title: Role of the CX3CL1 C-terminus in reversing age-dependent Alzheimers neurodegeneration
Funded at University of Connecticut Sch of Med/dnt · NIH-10594845 · Data updated 2026-11-12
This study is looking at a special protein that might help protect brain cells and improve thinking skills in people with Alzheimer's by reducing stress on those cells, and researchers hope it could lead to new treatments for the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Sch of Med/dnt NIH-funded |
| Lab location | 1 site (Farmington, United States) |
| Project start | December 15, 2022 |
| Project end | November 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $2,132,716 |
| NIH project number | 2RF1AG058261-03 |
| Project ID | NIH-10594845 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults diagnosed with Alzheimer's disease or those showing early signs of cognitive decline.
✕Less likely to help
Patients with early-stage Alzheimer's or other forms of dementia who are not yet experiencing significant cognitive impairment may not benefit from this research.
What this research studies
This research focuses on understanding how a specific peptide derived from the CX3CL1 protein can help reverse neurodegeneration associated with Alzheimer's disease. The study aims to explore the peptide's ability to reduce cellular stress and promote neuroprotection, potentially improving cognitive functions in patients. By examining the effects of this peptide on neuronal cells, researchers hope to identify new therapeutic strategies that not only target amyloid plaques but also enhance neural health. The approach involves pre-clinical testing to evaluate the peptide's effectiveness in mitigating the harmful effects of Alzheimer's pathology.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve cognitive function and quality of life for individuals with Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in using similar peptides for neuroprotection, indicating a potential for success in this novel approach.
Where this research is happening
-
University of Connecticut Sch of Med/dnt
Farmington, United States Active
Researchers
- Principal investigator: Yan, Riqiang — University of Connecticut Sch of Med/dnt
- Study coordinator: Yan, Riqiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.